To view this email as a web page, click here

Today's Rundown

Featured Story

Pieris Pharma nabs $20M upfront from Roche's Genentech for respiratory, ophthalmology pact

Pieris Pharmaceuticals has tapped another Big Pharma in its collaboration efforts, this time striking a $20 million upfront deal with Roche's Genentech.

read more

Top Stories

Bristol Myers taps Xencor’s half-life tech for COVID-19 antibody

Bristol Myers Squibb was a late entrant to the COVID-19 therapeutics space, picking up a pair of antibody treatments from Rockefeller University in February this year. Now, as the combination makes its way through phase 1 trials, the Big Pharma is licensing technology from Xencor that extends the treatment’s half-life.

read more

Mexico ramping up COVID-19 trial work tapping Sanofi, China's shots in late-stage tests

French Big Pharma Sanofi, using its traditional vaccine approach, and Chinese biotech Walvax, using mRNA technology, are both set to start phase 3 trials in Mexico.

read more

New JV from upstart biotechs Pyxis, Alloy aims for rapid drug development in cancer, autoimmune diseases

Kyma Therapeutics from Alloy Therapeutics and Pyxis Oncology will work on immune-modulating targets selected in cancer and autoimmune diseases. The candidates will be developed to what Alloy and Pyxis call a “value-inflection point,” at which point the companies expect they will be eligible for independent funding and partnering with other pharmas.

read more

Xilio inks Merck deal to run checkpoint inhibitor combo trial

Xilio Therapeutics has struck a deal with Merck to test its anti-CTLA-4 monoclonal antibody XTX101 in combination with Keytruda. The agreement sets Xilio up to show whether it can combine the checkpoint inhibitors without causing the toxicities associated with other cocktails that target CTLA-4 and PD-1. 

read more

GenSight's mutation-agnostic gene therapy triggers partial vision recovery

GenSight Biologics has reported the partial recovery of the vision of a retinitis pigmentosa patient treated with its mutation-independent approach to the restoration of visual function.

read more

Pharmacy giant CVS Health launches new clinical trial services biz, eyes siteless trials platform

CVS Health has navigated a pandemic that decimated footfall into its pharmacies but boosted demand for diagnostics and also saw it help pharma companies and CROs find trial subjects for COVID-19 tests.

read more

A 'springboard' to the future: Genentech, Sanofi and Alnylam execs sound off on pharma's evolving back-to-work plans

Top pharma HR executives know that bringing the work-from-home crowd back to the office is a chance to completely rethink how and where people do their jobs. In interviews, execs from three drugmakers—Sanofi, Alnylam and Genentech—explained how their companies are doing just that.

read more

Resources

eBook: Improving Diversity and Inclusion in Clinical Trials

Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them.

Whitepaper: Closed Cell Processing System Benefits for Cell & Gene Therapy

Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process.

Guide: Your Guide to Overcome Inconsistent Clinical Data Standards

Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials.

Whitepaper: The Journey to a Global Modular Content Strategy

One top 10 pharma outlines three key steps to launching a modular content strategy to generate localized content faster.

E-Book: 7 Keys to Success in Europe

This 77-page e-book explores 7 keys to success that any biopharma company needs to keep in mind as it enters Europe.

Executive Brief: Seven Secrets to Patient Experience Breakthroughs: Improving the Patient Experience and Study Retention

The average clinical trial spends $40,000 per patient. Yet despite these high costs, most trials struggle to retain patients.

Article: Make the right move at every step of the drug commercialization process

Developing a quality product and getting it approved for distribution is not enough to guarantee commercial success.

eBook: The New Standard: Virtual Study Training in Clinical Trials

The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today.

Content Hub: Process Intensification Resource Center

A one-stop hub for Cytiva resources to support process intesification

Whitepaper: COVID-19 Survey report: The Lasting Impact on Outsourcing Decisions

How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond?

Content Hub: Emerging Biotech Resource Center

A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule

Whitepaper: Roche to pick up GenMark Diagnostics in $1.8B infectious disease testing deal

Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously.

Content Hub: Remarque Systems Resource Hub

Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. 

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Executive Summary: Manufacturing Strategies to Effectively Industrialize Autologous Cell Therapies

Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Whitepaper: Achieving a Successful Drug Product Technology Transfer

Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.

Whitepaper: The Art of Recognizing Clinical Supply Risk Factors

In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management.

eBook: Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

Events